DDInter1821 DDInter915
Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury. It may also be caused by musculoskeletal injury. Regardless of the cause, muscle spasticity can be an extremely painful and debilitating condition. Initially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons promoting muscle spasm [FDA label].
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Tizanidine {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Cardiac disorder {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Tizanidine {u} (Compound) downregulates {v} (Gene) ADI1
ADI1 {u} (Gene) is downregulated by {v} (Compound) Procaterol
Procaterol {u} (Compound) resembles {v} (Compound) Indacaterol
Tizanidine {u} (Compound) downregulates {v} (Gene) EBNA1BP2
EBNA1BP2 {u} (Gene) is regulated by {v} (Gene) UGT1A1
UGT1A1 {u} (Gene) is bound by {v} (Compound) Indacaterol
Tizanidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salbutamol
Salbutamol {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Tizanidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salbutamol
Salbutamol {u} (Compound) binds {v} (Gene) ADRB1
ADRB1 {u} (Gene) is bound by {v} (Compound) Indacaterol
Tizanidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Formoterol
Formoterol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Adrenergic beta2-Agonists {u} (Pharmacologic Class) includes {v} (Compound) Indacaterol
Tizanidine {u} (Compound) binds {v} (Gene) ADRA2A
ADRA2A {u} (Gene) interacts with {v} (Gene) ADRB1
ADRB1 {u} (Gene) is bound by {v} (Compound) Indacaterol
Tizanidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Formoterol
Formoterol {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Cardiac disorder {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Tizanidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dextromethorphan
Dextromethorphan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Indacaterol
Tizanidine {u} may lead to a major life threatening interaction when taken with {v} Vemurafenib
Vemurafenib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Indacaterol
Tizanidine (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Indacaterol (Compound)
Tizanidine (Compound) downregulates ADI1 (Gene) and ADI1 (Gene) is downregulated by Procaterol (Compound) and Procaterol (Compound) resembles Indacaterol (Compound)
Tizanidine (Compound) downregulates EBNA1BP2 (Gene) and EBNA1BP2 (Gene) is regulated by UGT1A1 (Gene) and UGT1A1 (Gene) is bound by Indacaterol (Compound)
Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol (Compound) treats asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)
Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol (Compound) binds ADRB1 (Gene) and ADRB1 (Gene) is bound by Indacaterol (Compound)
Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class) and Adrenergic beta2-Agonists (Pharmacologic Class) includes Indacaterol (Compound)
Tizanidine (Compound) binds ADRA2A (Gene) and ADRA2A (Gene) interacts with ADRB1 (Gene) and ADRB1 (Gene) is bound by Indacaterol (Compound)
Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Indacaterol (Compound)
Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indacaterol (Compound)
Tizanidine may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indacaterol (Compound)